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Although the progression of chronic lymphocytic leukemia (CLL) requires the cooperation of the microenviron-
ment, the exact cellular and molecular mechanisms involved are still unclear. We investigated the interleukin 
(IL)–23 receptor (IL-23R)/IL-23 axis and found that circulating cells from early-stage CLL patients with shorter time- 
to-treatment, but not of those with a more benign course, expressed a defective form of the IL-23R complex lack-
ing the IL-12R1 chain. However, cells from both patient groups expressed the complete IL-23R complex in tissue 
infiltrates and could be induced to express the IL-12R1 chain when cocultured with activated T cells or CD40L+ 
cells. CLL cells activated in vitro in this context produced IL-23, a finding that, together with the presence of IL-23 
in CLL lymphoid tissues, suggests the existence of an autocrine/paracrine loop inducing CLL cell proliferation. In-
terference with the IL-23R/IL-23 axis using an anti–IL-23p19 antibody proved effective in controlling disease on-
set and expansion in xenografted mice, suggesting potential therapeutic strategies.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) involves the monoclonal expan-
sion of CD5+ B lymphocytes in the bone marrow, peripheral blood, and 
lymphoid organs (1). Most patients present with an indolent disease 
and may not require treatment for many years, whereas a minority of 
patients (about 30%) display a rather aggressive disease course requir-
ing early treatment. Clinical heterogeneity may be attributed to both 
clone-intrinsic biological features and clone-extrinsic events, given the 
fact that signals from the surrounding microenvironment are increas-
ingly recognized as determinants of clone fitness and progression (2–5).
The mechanisms underlying CLL cell clonal expansion are only 
partially understood. In vivo cell kinetic studies in patients have demon-
strated that CLL cells have a substantially higher proliferative rate than 
originally estimated, which challenged the view that the CLL clone en-
dorses minimal proliferative capacity despite conspicuous resistance 
to cell death (6, 7). Proliferation of CLL cells occurs primarily in pe-
ripheral lymphoid organs, specifically within the so-called prolifer-
ating centers of infiltrated lymphoid tissues, and is driven by signals 
delivered by the surrounding cells, by cytokines, and even by the CLL 
cell B cell receptor (BCR) (8–10). Furthermore, proinflammatory cyto-
kines have been variably demonstrated to identify CLL subsets having 
more aggressive disease and worse survival (11, 12). Finally, many CLL 
clones express BCR with polyreactivity and/or self-reactivity, which 
could bind (although with low affinity) to a number of self-antigens 
expressed by surrounding cells, contributing to their activation and 
subsequent susceptibility to growth signals (13, 14). Likewise, a similar 
function may be exerted by the recognition of antigens exposed by apop-
totic cells or of internal epitopes of the CLL BCR itself (15–18).
Interleukin-23 (IL-23) is a pleiotropic cytokine of the IL-6 super-
family involved in the bridging of adaptive and innate immunity and 
in tissue remodeling (19). IL-23 is a heterodimeric cytokine composed 
of a p19 subunit and a p40 subunit, which is common to IL-12. IL-23 
is predominantly produced by myeloid dendritic cells and type 1 mac-
rophages in response to microbial or host immune stimuli and is in-
volved in the regulation of immune responses against infections and 
tumor development through the engagement of the IL-23 receptor 
(IL-23R) (20–22). The IL-23R is a heterodimeric complex consist-
ing of an IL-12R1 chain (also common to the IL-12R) and a specific 
IL-23R subunit (22). To date, the demonstration of functional IL-
23R complex expression in normal B cells has been confined to early 
B lymphocytes, germinal center B cells, and plasma cells (23, 24). The 
IL-23R heterodimer is also expressed by acute lymphoblastic leukemia 
(ALL) cells, follicular lymphoma (FL), diffuse large B cell lymphoma 
(DLBCL), and myeloma cells (23–26).
Here, we demonstrate that circulating CLL cells of early-stage, Binet A 
patients variably express the IL-23R subunit in the absence of the IL-12R1 
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chain and that the expression of the IL-23R subunit positively cor-
relates with adverse prognostic factors and a higher risk of therapy 
need. We also provide evidence of a regulation of the IL-23R com-
plex by the microenvironment and unveil an autocrine/paracrine 
loop involving IL-23R complex up-regulation and IL-23 synthesis 
in CLL clones. Finally, we demonstrate that this loop may represent a 
therapeutic target because in vivo treatment with an anti–IL-23p19 
monoclonal antibody (mAb) (IL-23p19) eradicated CLL clones in 
xenografted mice.
RESULTS
Uncoupled IL-23R expression characterizes  
circulating peripheral CLL cells and identifies high-risk 
early-stage patients
The surface expression of the two chains of the IL-23R complex (IL-23R 
and IL-12R1 subunits) was investigated in circulating CLL cells of 
57 consecutive Binet stage A patients enrolled in a multicenter pro-
spective trial. Although the expression of the IL-23R chain varied from 
high to low (Fig. 1, A to C), that of IL-12R1 was consistently low or 
absent in CLL cells (gated as CD19+CD5+ cells) from all the peripheral 
blood mononuclear cell (PBMC) suspensions analyzed (Fig. 1C). The 
uncoupled expression of IL-23R and IL-12R1 side chains was also 
confirmed by double-marker immunofluorescence (IF) studies using 
cytospin preparations (Fig. 1B). IL-23R was expressed by T cells and 
natural killer (NK) cells from the same CLL cases, which also showed 
a substantial proportion of IL-12R1+ cells (see Fig. 1D). No signifi-
cant differences were observed in the expression of the IL-23R complex 
by T cells and NK cells from CLL cases classified as IL-23R–positive 
or IL-23R–negative (see Fig. 1).
The study of IL-23R expression was extended to the PBMCs of 
an additional 209 CLL patients in the trial. The variability of IL-23R 
chain expression (median percentage expression, 26%; range, 3.9 to 
91.2) (Fig. 1E) allowed stratification of patients into two groups desig-
nated as IL-23Rhigh (≥23%, n = 152) or IL-23Rlow (<23%, n = 114), based 
on receiver operating curve (ROC) analysis (as described in Materials 
and Methods). Notably, IL-23R chain expression was significantly 
correlated only with immunoglobulin heavy chain variable region 
(IGHV) gene mutational status (P = 0.049) when considered together 
with other prognostic markers (table S1).
Clinical information was available for 219 cases, and we could 
explore a possible correlation between IL-23R chain expression by 
CLL cells and time to first treatment (TTFT). Of these cases, 63 met 
the more recent diagnostic criteria of clinical monoclonal B lympho-
cytosis (MBL) (27, 28). The median follow-up was 36 months (range, 
6 to 63 months); 8 of 97 IL-23Rlow and 26 of 122 IL-23Rhigh CLL cases 
progressed and required treatment. The 3-year TTFT probability 
of IL-23Rlow patients was 91.6% compared to 85.0% of IL-23Rhigh cases 
(Fig. 1E). Univariate Cox analysis showed that CD38-positive, 
IGHV gene–unmutated, zeta chain–associated protein kinase 70 (ZAP-
70)– positive cases and patients with a peripheral B lymphocytosis 
of ≥5000/mm3 had a higher risk of starting treatment compared to 
CD38-negative, IGHV gene–mutated, ZAP-70–negative, and MBL cases. 
In a Cox multivariate model, IL-23R chain expression remained sig-
nificant [hazard ratio (HR) = 2.8, 95% confidence interval (CI) = 1.2 to 
6.5, P = 0.014] in predicting TTFT, together with IGHV gene muta-
tional status and B lymphocytosis ≥5000/mm3 (Fig. 1F). The same 
analysis carried out by a bootstrapping Cox regression model pro-
vided similar results (table S2).
Complete IL-23R complex expression is dependent on the 
CLL tissue microenvironment
Next, we investigated whether the uncoupled expression of the two 
chains of the IL-23R complex also characterized CLL cells within 
the tissue microenvironment. First, we evaluated the expression of 
the IL-23R chain in tissue samples from 16 CLL patients, collected 
at diagnosis using in situ immunolocalization analyses. A variable 
expression of the IL-23R chain was observed in CLL lymph node 
(LN) infiltrates, which comprised cases with few scattered IL-23R chain– 
expressing cells intermingling with a majority of IL-23R chain–negative 
elements (10 of 16 cases) (Fig. 2A, left) and cases with a prominent 
IL-23R chain expression in the majority of the lymphoid infiltrates 
(6 of 16) (Fig. 2A, right). The large majority of IL-23R chain–expressing 
cells also expressed CD20 (Fig. 2B, left). IL-12R1 was present with-
in LN infiltrates of IL-23R chain–positive CLL cases, and its expres-
sion mainly characterized CD20-positive CLL cells (Fig. 2B, right). 
Double-marker IF analysis showed that IL-12R1 expression was 
not homogeneous, being highly expressed and colocalized with the 
IL-23R chain in some areas of the LN infiltrates or barely expressed 
in other LN areas despite a high IL-23R chain staining (Fig. 2C). 
Double-marker IF analyses revealed that, within CLL nodal infil-
trates, those areas showing dense macrophage infiltration or higher 
CD40L expression also corresponded to areas with higher IL-12R1 
expression (Fig. 2, D and E).
Costimulatory signals modulate in vitro IL-12R1 chain 
expression in CLL
Next, we analyzed whether CLL cell activation resulted in up- 
regulation of either IL-23R or IL-12R1 or both receptors. First, we 
cocultured purified CLL cells in the presence of a CD40L-expressing 
murine NIH-3T3 cell line (CD40L-TC) or with control cells stably 
transfected with the plasmid internal ribosomal entry site (pIRES) 
vector alone (Mock) (29). After 24 to 48 hours of culture, we found 
a slight, although significant, induction of the IL-23R chain and a 
significant up-regulation of IL-12R1 expression in both IL-23R high 
and IL-23Rlow cases (Fig. 3A). The cells positive for the IL-23R chains 
were identified within the gated populations of viable cells (fig. S1, 
A and B), which also comprised CD80+ and CD86+ cells (fig. S1, C 
and D). The small cells shown in both Fig. 3A and fig. S1 consisted 
of annexin V/propidium iodide (PI) double-positive dead cells (see 
fig. S1, A and B). Figure 3B summarizes data from 13 CLL cases (3 of 
13 being IL-23Rlow before culture; table S3). In all cases, up-regulation 
of the IL-23R complex was observed, together with the induction of 
the IL-12R1. Overall, these phenomena were more marked in the 
CLL cases classified as IL-23Rhigh. These data were corroborated by 
the observation of an increased production of IL-12R1 mRNA by 
stimulated CLL cells (see fig. S2).
The IL-23R complex expression was similarly induced upon cul-
turing PBMCs from CLL patients in the presence of CD3/CD28 
beads and IL-2 (Fig. 3, C and D). Under these conditions, autologous 
T cells present in the suspensions were activated and could, in turn, 
activate CLL cells. At the end of the culture, the cells were analyzed by 
flow cytometry. Only viable cells were gated, and the CLL cells present 
in the suspension were identified as CD5+CD19+ cells. This gated 
CLL cell population was evaluated for the expression of the IL-23R 
complex (Fig. 3C). To demonstrate that IL-23R complex up-regulation 
was not simply due to a selection of preexisting IL-23R complex–
positive subclones, PBMCs from CLL patients were depleted of IL-
23R complex– positive cells using immunomagnetic separation beads 
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Fig. 1. Evaluation of IL-23R and IL-12R1 chain expression in CLL. (A) Two representative chronic lymphocytic leukemia (CLL) cases, with low and high interleukin-23 
receptor (IL-23R) expression, respectively, analyzed by flow cytometry. CLL cells were gated as CD19+CD5+ cells. IgG1, immunoglobulin G1. (B) IL-23R and IL-12R1 chain 
expression evaluated by immunocytochemistry on cytospin smears of CLL peripheral blood samples. DAPI, 4′,6-diamidino-2-phenylindole. (C) IL-12R1 chain expression 
in 57 consecutive cases featuring different IL-23R chain expression. (D) Expression of IL-23R and IL-12R1 by CD5+CD19− [T cells + natural killer cells (T + NK cells)] from 
the peripheral blood of the same CLL cases shown in (C) (n = 57). Statistical comparisons were carried out by Wilcoxon tests. Asterisks indicate statistically significant 
P values (P < 0.05). (E) Kaplan-Meier curves comparing time to first treatment of IL-23Rhigh (n = 97) or IL-23Rlow (n = 122) CLL cases. Statistical significance of associations 
between individual variables and survival was calculated using the log-rank test. (F) Cox multivariate analysis showing that IL-23R chain expression maintains an indepen-
dent prognostic impact in the presence of other prognostic indicators (P = 0.014). HR, hazard ratio; CI, confidence interval; cMBL, clinical monoclonal B lymphocytosis; 
IGHV, immunoglobulin heavy chain variable region; ZAP-70, zeta chain–associated protein kinase 70.
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before autologous T cell activation (fig. S3). 
After depletion and stimulation, expression of 
the IL-23R complex was observed, supporting 
the notion of de novo expression of receptor 
structures upon engagement of costimulatory 
pathways. CLL cells cultured with stimulated 
T cells were induced to up-regulate both acti-
vation (CD38; Fig. 3, E and F) and proliferation 
(Ki67; Fig. 3, G and H) markers. Consistent-
ly, within areas of high IL-12R1 expression in 
tissue sections, CLL cells showed increased 
Ki67 signals (Fig. 3I).
CLL cells produce IL-23 in vivo  
and in vitro
Subsequently, we investigated the presence of 
IL-23 in LN tissue specimens from CLL pa-
tients. There were two groups of LNs, that is, 
those that were strongly IL-23–positive (Fig. 4A, 
left) and those that were almost IL-23–negative 
(Fig. 4A, right). This distribution was similar 
to that already shown for IL-23R (see Fig. 2A). 
There was a clear correlation between the pres-
ence of IL-23R and IL-23 in the same infil-
trated tissue areas (as shown in Fig. 4B).
A definite increase of IL-23 secretion was ob-
served in CLL cell supernatants after prim-
ing with CD40L-TC (n = 18) or activated 
autologous T cells (n = 7) (Fig. 4, C and D). Fi-
nally, the CLL cells that expressed the IL-23R 
complex upon in vitro activation with CD40L- 
TC were also those that contained abundant 
intracytoplasmic IL-23 chains as assessed by 
flow cytometry (see fig. S4).
Fig. 2. Analysis of CLL lymph nodes. (A) Two representative 
cases (of the 16 examined) expressing low (n = 10) or 
high (n = 6) IL-23R chain (magnification, ×200). (B) Double- 
marker immunofluorescence (IF) analysis of IL-23R chain 
(left) or IL-12R1 chain (right) and CD20 in a representative 
lymph node displaying high expression of the IL-23R 
chain (n = 6 of 16) (magnification, ×200). (C) Double- 
marker IF analysis of IL-23R and IL-12R1 showing foci of 
higher and lower IL-12R1 expression (dashed circles; 
magnification, ×100). (D) Double-marker IF analysis 
of IL-12R1 and CD68 showing higher expression of 
IL-12R1 in foci with higher CD68-expressing cell density. 
(E) Double-marker IF analysis showing different repre-
sentative areas of the same lymph node with lower 
(top) and higher (bottom) IL-12R1 expression and cor-
responding CD40L expression (magnification, ×200). (B to 
E) Microphotographs are relative to one representative 
lymph node (of six evaluated) displaying IL-23Rhigh chain. 
IF microphotographs are representative of analyses on 
at least 5 for low-power magnification (×100) or 10 for 
high-power magnification (×200 and ×400) micro-
scopic fields performed on each lymph node sample.
 by guest on February 22, 2018
http://stm
.sciencem
ag.org/
D
ow
nloaded from
 
Cutrona et al., Sci. Transl. Med. 10, eaal1571 (2018)     14 February 2018
S C I E N C E  T R A N S L A T I O N A L  M E D I C I N E  |  R E S E A R C H  A R T I C L E
5 of 15
Collectively, these data suggest that the CLL microenvironment elicits 
an autocrine/paracrine loop involving IL-23R complex up-regulation and IL-23 
synthesis. Notably, in vitro IL-23 production could be induced in all CLL 
clones irrespective of whether they were initially classified as IL-23Rhigh 
or IL-23Rlow.
IL-23R complex expression is minimally induced or not 
induced after coculture of CLL cells with stromal cells or 
nurse-like cells or after BCR cross-linking
We evaluated whether coculture of CLL cells with stromal cells or nurse- 
like cells (NLCs) results in the induction of IL-23R complex expression. 
Fig. 3. In vitro induction of 
IL-12R1 chain expression. 
(A) Peripheral mononuclear 
CLL cells from two representa-
tive CLL cases (IL-23Rlow and 
IL-23Rhigh, respectively) were 
cocultured with C D 4 0 L - 
expressing NIH-3T3 (CD40L-TC) 
or control NIH-3T3 cells ex-
pressing an empty vector 
(Mock) for 48 hours and then 
analyzed for IL-23R complex 
expression by flow cytometry. 
Only viable cells were gated, 
as indicated (left), and of these, 
CD5+CD19+ cells (middle) were 
analyzed for IL-23R chain ex-
pression (right). For further 
details, see fig. S1. SSC-H, side 
scatter height; FSC-H, forward 
scatter height. (B) Time course 
analysis of IL-23R complex 
(top), IL-23R (middle), and 
IL-12R1 (bottom) chains eval-
uated by flow cytometry be-
fore (T0) and after CD40L 
engagement in 13 CLL cases. 
See table S3 for a summary 
of patient features. The P values 
shown are relative to 48-hour 
cell cultures (Wilcoxon test). 
(C) Time course experiments 
showing a representative test 
on a CLL case (PD601). Periph-
eral blood mononuclear cells 
(PBMCs) were cultured in me-
dium alone or in the presence 
of CD3/CD28 beads and IL-2, 
and cells were harvested at 
the indicated times. Analysis 
of the IL-23R chain expression 
(bottom) was carried out on 
CLL cells gated for CD5 and 
CD19 (top). (D) IL-23R-complex 
expression by the CLL cells of 
14 cases analyzed after a 
120-hour coculture, as described 
in (C). P value shown (***P = 
0.0001) refers to the three 
pairs analyzed (Wilcoxon test). 
(E) CD38 expression on CLL cells 
after a 120-hour culture in 
presence of autologous activated T cells and (F) evaluation of IL-23R complex expression on CD38-positive or CD38-negative cells (n = 11 CLL cases) (Wilcoxon test). (G) Ki67 
expression by IL-23R complex–positive and IL-23R complex–negative CLL cells, respectively. CLL cells, cultured in the presence of activated autologous T cells as in (D), were 
stained for the indicated receptor chain. CD5+CD19+ CLL cells were gated and evaluated for both Ki67 and IL-23R chain expression. (H) Mean and SEM of Ki67 expression by 
the cells from six CLL cases treated and analyzed as described in (G) (Wilcoxon test). (I) Double-marker IF analysis showing different representative areas of the same lymph 
node with lower (left) and higher (right) IL-12R1 expression and corresponding Ki67 expression (magnification, ×200). IF microphotographs are relative to a representative 
lymph node (of six evaluated) displaying IL-23Rhigh chain and of at least 10 microscopic fields performed on each lymph node sample.
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Coculture with the HS5 stromal cell line enhanced IL-23R complex 
expression by CLL cells, although the observed increase was lower than 
that obtained by cocultures with CD40L-TC or with activated T cells. 
In contrast, there was no significant up- 
regulation of the IL-23R complex after 
coculture of CLL cells with NLCs. Con-
sistent with this is the observation that 
HS5 stromal cells and NLCs were CD40L- 
negative [fig. S5 and (30)]. However, when 
PBMCs of CLL patients, rather than highly 
purified CLL cells, were cocultured with 
NLCs, there was an up-regulation in the 
expression of the IL-23R complex (fig. S6). 
As expected from previous data (30–32), 
there was an inhibition of spontaneous CLL 
cell apoptosis in both culture conditions. 
The data are summarized in fig. S7.
No significant release of IL-23 cyto-
kine (mean ± SEM) was detected in the 
culture supernatants of CLL cells cultured 
with medium or with autologous NLC for 
7 days (n = 4 CLL cases, 6.44 ± 0 pg/ml 
versus 1.46 ± 0 pg/ml, respectively) or 
for CLL cells cultured with medium or with 
HS5 stromal cells for 72 hours (n = 8 CLL 
cases, 6 ± 1.2 pg/ml versus 3.6 ± 1.6 pg/ml, 
respectively), which led us to the conclusion 
that the IL-23R complex/IL-23 loop was not 
activated under these culture conditions.
We also investigated whether BCR 
stimulation of purified CLL cells could 
induce IL-23R complex expression. Ex-
posure to insolubilized anti- antibody 
(G-Ab) failed to induce IL-23R complex 
expression even in the presence of IL-4 
[fig. S8, A and B, and (33)]. This treatment 
induced phosphorylation of Bruton’s ty-
rosine kinase (pBTK) and increased cell 
viability in culture (fig. S8B).
We also investigated whether the BCR 
pathway was involved when CLL cells were 
induced to express the IL-23R complex 
by contact with CD40L-TC. To this end, 
purified CLL cells were incubated with 
the BTK inhibitor ibrutinib (1 M) 1 hour 
before coculturing with CD40L-TC or 
mock cells (fig. S8). After ibrutinib expo-
sure, the IL-23R complex was still detect-
able, although on a smaller percentage 
of cells (fig. S8C). This treatment caused 
inhibition of pBTK and decreased cell 
viability, as shown in fig. S8 (D and E).
IL-23 acts as a growth factor for 
CLL cells
Next, we investigated whether IL-23 
could facilitate survival and expansion 
of activated CLL cells in culture. PBMCs 
from CLL patients were exposed to 
CD3/CD28 beads for 120 hours in culture, and the CLL cells were 
subsequently separated from T cells by negative selection using an 
EasySep Human B Cell Enrichment Kit and then recultured in the 
Fig. 4. IL-23 production by CLL clones. (A) Immunohistochemistry (IHC) evaluation of two representative cases of 
CLL lymph node specimens (of the 16 examined) producing higher (n = 6) or lower (n = 10) levels of IL-23 (magnifica-
tion, ×200). (B) Double-marker IF and confocal microscopy analysis of IL-23R chain and IL-23 or IL-12R1 chain and 
IL-23 or DAPI of a representative CLL lymph node displaying IL-23Rhigh chain (of six analyzed) showing production of 
IL-23 cytokine by IL-23R complex–expressing cells (magnification, ×200). Microphotographs in (A) and (B) are repre-
sentative of analyses of at least 10 microscopic fields performed on each lymph node sample. (C) IL-23 production in 
supernatants of cells from 18 CLL cases cultured in the presence of CD40L-TC or control (Mock) fibroblasts. (D) IL-23 
production by CLL cells induced by contact with activated autologous T cells. PBMCs from seven CLL cases were cul-
tured in the presence of CD3/CD28 beads and IL-2 or in medium alone for 120 hours. At the end of this period, CLL cells 
were depleted of T cells by negative selection and placed in culture for an additional 24 hours before measuring IL-23 
concentrations (in picograms per milliliter) in the supernatant. P values of the difference between stimulated CLL cells 
and controls are indicated (Wilcoxon test). Asterisks indicate statistically significant P values (P < 0.05).
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presence or absence of IL-23 for an additional 48 hours. A signifi-
cantly increased viability and a higher Ki67 expression were ob-
served in IL-23–treated CLL cells compared to control cells not 
exposed to IL-23 (Fig. 5, A and B). Addition of IL-23 neutralizing 
mAb (IL-23p19) to CLL cultured alone resulted in decreased cell 
viability and proliferation, indicating that there was a production of 
IL-23 in the culture acting in an autocrine/paracrine manner. This 
effect of IL-23p19 was largely inhibited by the addition of exoge-
nous IL-23, indicating that the antibody was indeed neutralizing the 
endogenously produced IL-23. In a subsequent series of experi-
ments, purified CLL cells were activated by coculturing with 
CD40L-TC for 72 hours and then exposed to small interfering 
RNAs (siRNAs) specific for IL-23A mRNA and IL-23R mRNA or to 
negative control siRNAs (see Supplementary Materials and 
Methods). As apparent from fig. S9, which shows the results of one 
representative experiment of three carried out on different cases, 
treatment with the appropriate siRNAs, but not with the control 
siRNAs, caused inhibition of IL-23 and IL-23R mRNA production, 
inhibition of IL-23R expression, and reduction of cell viability and 
proliferation.
Different intracellular kinase inhibitors were added to purified 
CLL cells cultured with IL-23 after a preactivation step with stimu-
lated autologous T cells. As shown in Fig. 5 (C and D), ibrutinib treat-
ment had virtually no effect on cell viability and proliferation, whereas 
tofacitinib [a pan–Janus kinase (JAK) inhibitor] and ruxolitinib (a spe-
cific JAK1/2 inhibitor) were effective in decreasing cell viability and 
particularly cell proliferation. The inhibitory kinase effect was also 
exerted in the presence of exogenous IL-23.
We further investigated the presence of phosphorylated signal 
transducer and activator of transcription 3 (pSTAT3) and pBTK pro-
teins after exposure of activated CLL cells to IL-23. pSTAT3 (but not 
pBTK) increased after cell exposure to IL-23 (Fig. 5E), and phosphoryla-
tion persisted in the cultured cells up to 48 hours (Fig. 5H). BTK was 
phosphorylated upon stimulation of purified CLL cells with G-Ab 
or G-Ab (anti- antibody) or with a combination thereof, provid-
ing an effective positive control (Fig. 5F). The preactivation step of 
CLL cells in culture with activated T cells caused an up-regulation 
of pSTAT3, which was rather heterogeneous and case-dependent 
(typical examples of this phenomenon are shown fig. S10). This 
pSTAT3 up-regulation produced a sort of background noise in the 
cells cultured in the absence of IL-23, which is visible in Fig. 5 
(G and I). However, the levels of pSTAT3 in the preactivated cell cul-
tures when reexposed to IL-23 were consistently higher (Fig. 5, 
G and I). Furthermore, there was a marked inhibition of pSTAT3 
detected by flow cytometry when preactivated CLL cells were cul-
tured with IL-23 in the presence tofacitinib and ruxolitinib (Fig. 5, J 
and K). Under these conditions, ibrutinib was ineffective on pSTAT3 
signals, although it had some effect on pBTK. Collectively, these 
data support the notion that the JAK/STAT pathway was primarily 
involved in IL-23 signaling to CLL cells and in sustaining cell prolif-
eration in vitro.
IL-23R complex expression is up-regulated in CLL cells 
growing in NSG mice
Next, we investigated whether the costimulatory signals inducing 
up-regulation of the IL-23R complex by CLL cell in vitro could be 
functionally recapitulated by tissue microenvironment signals in vivo. 
PBMCs from an IL-23Rlow CLL case (PM608; Fig. 6A) were inocu-
lated into NOD/Shi-scid,cnull (NSG) mice (34). Eight weeks after 
cell injection, mice were sacrificed, and spleen and liver were ana-
lyzed for CLL cell infiltration (Fig. 6, B to D). Neoplastic cell infiltrates, 
highlighted by human CD20 immunoreactivity, were found in as-
sociation with patient-derived T cells, identified mainly as human 
CD4+ and, to a lesser extent, human CD8+ cells (Fig. 6B). Moreover, with-
in splenic and hepatic infiltrates, CLL cells showed a high prolifera-
tive rate, as suggested by double-marker immunostaining for human 
CD20 and Ki67 (Fig. 6C). CD20-positive xenografted CLL cells, which 
expressed low levels of both IL-23R and IL-12R1 chains at base-
line, showed consistent up-regulation of both chains of the IL-23R 
complex within murine splenic and hepatic infiltrates (Fig. 6C). Co-
expression of IL-23R and IL-12R1 chains was confirmed by flow 
cytometry (Fig. 6D). Notably, double-marker confocal microscopy 
analysis and flow cytometry showed that CLL cells also synthesized 
IL-23 within murine tissue infiltrates (Fig. 6, E and F). Similar im-
munohistochemical patterns of staining for IL-23R complex were 
observed in three additional xenografting experiments using PBMCs 
derived from three CLL cases with different baseline levels of IL-23R 
expression [ZC0010 (8.1%), MG0248 (19.5%), and CD0310 (23.7%); 
fig. S11]. Table S4 reports the features of the cells from different CLL 
cases (n = 22) used throughout this study; immunohistochemistry 
(IHC) patterns of CLL cell infiltration similar to those described 
above were observed in mice xenografted with CLL cells from dif-
ferent cases and with different characteristics. Engraftment was 
measured by determining the IHC index, derived from the combi-
nation of size and numbers of CD20-positive follicles in the spleen 
[see (35), the Supplementary Materials, and Materials and Methods]. 
Engraftment capacities of the different CLL clones in NSG mice were 
similar regardless of whether they were classified as IL-23Rhigh or 
IL-23Rlow.
Interruption of the IL-23R/IL-23 loop has therapeutic  
effects in vivo
We next investigated the in vivo effect of IL-23p19 mAb-based 
treatment (36). Eighteen NSG mice were xenografted with circu-
lating PBMCs from three different CLL cases (PA0146, GA0626, 
and GE1-BA101, which were xenografted in 4, 4, and 10 mice, re-
spectively). After 4 to 6 weeks, all mice showed leukemia engraft-
ment, based on the flow cytometry detection of circulating human 
CD45+CD19+CD5+ cells. At this point, mice were treated either with 
one dose of an anti- human IL-23p19 mAb or with the isotype con-
trol antibody in each of the days indicated in Fig. 7A. The amount 
of CLL cells detected in different compartments, evaluated 3 days 
after the last treatment, was significantly higher in mice treated 
with the isotype control compared with mice treated with the IL-
23p19 mAb, irrespective of tissues where the analysis was performed 
(Fig. 7B). Moreover, IHC analysis of human CD20-expressing CLL 
cells showed that mice treated with the neutralizing IL-23p19 mAb 
were virtually free of disease infiltration and presented a few cells 
containing human IL-23 compared to controls (Fig. 7, C and D). In 
the spleen of mice freed of the disease after treatment, foci of stromal 
remodeling indicative of former parenchymal infiltration could be 
detected morphologically (Fig. 7, C and D). Notably, mice treated 
with IL-23p19 mAb showed increased apoptosis in CLL cells (Fig. 7, 
E and F) as compared with isotype control–treated mice. Consis-
tently, in mice treated with IL-23p19 mAb, there was a decrease of 
Ki67-positive CLL cells as assessed by double-marker IF and flow 
cytometry analyses on spleen infiltrates (Fig. 7, G to I). Notably, mo-
lecular testing for the specific BCR rearrangement of the CLL clone 
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Fig. 5. Functional analysis of IL-23 
signaling in CLL cells. (A) Flow cy-
tometry determination of viable cells 
[annexin V/propidium iodide (PI)–
negative cells] or of (B) Ki67-positive 
CLL cells. PBMCs from CLL patients 
were cultured with CD3/CD28 beads 
+ IL-2 (120 hours). Subsequently, CLL 
cells were purified by negative se-
lection and recultured for 48 hours 
in the presence or absence of IL-23 
(100 ng/ml) or of IL-23 neutralizing 
monoclonal antibody (mAb) (IL-
23p19) in the indicated combinations. 
(C and D) PBMCs from CLL patients 
were cultured with CD3/CD28 beads 
+ IL-2 for 120 hours as in (A) and (B). CLL 
cells were subsequently purified by 
negative selection and recultured 
in the presence of the indicated ki-
nase inhibitors with or without IL-23. 
Cell viability and Ki67 expression 
were determined after a 48-hour 
culture. Each dot represents a test on 
a different CLL case. Mean ± SEM 
are given. Statistical analysis was car-
ried out using Wilcoxon (A to C) or 
Mann-Whitney U tests (D). Asterisks 
indicate statistically significant 
P values (P < 0.05). (E) Immunoblotting 
analysis of signal transducer and 
activator of transcription 3 phos-
phorylation (pSTAT3) and Bruton’s 
tyrosine kinase phosphorylation 
(pBTK) in purified CLL cells (from 
case RD0468; 52% IL-23R–positive 
cells) activated with T cells as in (A), 
purified and stimulated at 37°C 
with IL-23 for the indicated times. 
(F) Phosphorylation of BTK and 
STAT3 was assessed in freshly isolated 
CLL cells after exposure to anti- anti-
body (G-Ab), anti- antibody (G-
Ab), or a combination of both, at 37°C 
for 5 min. CTR, control. (G) Summary 
of data from five tests of STAT3 
phosphorylation on different CLL 
cases: Data are presented as pSTAT3/
total STAT3 (tSTAT3) ratio after a 
10-min and 30-min incubation with 
IL-23. (H) CLL cells (from case AM609; 
53% IL-23R–positive cells) were in-
duced to express the IL-23R com-
plex as in (A), purified and exposed 
to IL-23 or medium alone for the indi-
cated times, and studied for the 
presence of pSTAT3 by flow cytome-
try (right). Left: Results obtained in 
CLL cells for which the preactivation 
step was omitted (PBMCs from CLL 
patients were cultured without CD3/
CD28 beads; CLL cells were purified and then exposed to IL-23 or medium alone for 1 hour). The degree of pSTAT3 was evaluated on viable cells gated as in Fig.  3A and as detailed 
in fig. S1. CD19 expression was also detected to verify the purity of the CLL cell isolation. (I) Summary of data on pSTAT3 induction (determined by flow cytometry) after a 48-hour 
exposure to IL-23 in activated and purified CLL cells [as in (A)] from five different CLL cases. (J and K) CLL cells from case GE1-CC45 (36% IL-23R–positive cells) were activated and 
purified as in (A) and cultured in the presence or absence of the indicated inhibitors for 48 hours, and pSTAT3-positive (J) or pBTK-positive (K) cells were measured by flow cytometry.
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Fig. 6. NSG mice model engrafted with CLL cells. A total of 50 × 106 PBMC cells from case PM608 were injected into three NOD/Shi-scid,cnull (NSG) mice intravenously. Mice 
were sacrificed and analyzed 4 weeks after the inoculum. (A) Flow cytometry analysis shows that the injected cells were IL-23Rlow (6.3% positive cells). (B) IHC analysis of tissue slices 
from engrafted mice showing spleen (top) and liver (bottom) infiltration by CLL cells stained by the indicated anti-human mAb (magnification, ×40). (C) IHC (top, magnification, ×400) 
and IF (middle and bottom, magnification, ×40) staining of paraffin-embedded tissue slice sections showing expression of IL-23R chains in areas characterized by cell prolifer-
ation (Ki67+ cells). (D) Flow cytometry analysis of the IL-23R complex in CLL cells in mouse spleen. PE, phycoerythrin. (E) Confocal microscopy image of the mouse spleen. 
The arrows indicate neoplastic CLL cells (human CD20+) producing human IL-23 (IL-23p19+) [magnifications, ×200 (left) and ×630 (right)]. (F) IL-23 chains in xenografted CLL cells 
measured by flow cytometry. Human IL-23 chains were detected by intracellular staining with IL-23p19 and IL-12/IL-23p40 antibodies on gated human CD45+CD19+ CLL cells. 
Microphotographs are representative of analyses on at least 10 for high-power magnification (×200 to ×630) microscopic fields performed on each mouse spleen tissue sample.
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of the donor patient was identified in different compartments of 
control antibody–treated mice and was not detected in mice achiev-
ing a complete remission as determined by flow cytometry evalua-
tion (fig. S12). The striking effect of IL-23p19 mAb treatment does 
not appear to be attributable to opsonization of CLL cells by IL-
23p19 mAb, which, in principle, could recognize the IL-23 bound 
Fig. 7. Treatment with neu-
tralizing IL-23 antibody 
(IL-23p19) inhibits CLL 
growth and proliferation 
in the NSG mouse model. 
(A) Treatment scheme of 
IL-23p19 or isotype CTR mAb 
in NSG mice. Mice were in-
jected with 50 × 106 CLL cells 
previously stimulated with 
autologous activated T cells. 
After 4 to 6 weeks, blood 
samples were evaluated for 
the presence of circulating 
leukemic cells by flow cy-
tometry before treatment 
with four doses of IL-23p19 
or isotype CTR mAbs every 
2 days. At the end of the ex-
periments, mice were sac-
rificed, and cell suspensions 
from the spleen, liver, bone 
marrow (BM), and periph-
eral blood were analyzed by 
flow cytometry for the per-
centage of neoplastic B cells 
(human CD5+CD19+ cells / 
total human CD45+ cells). 
(B) The mean and SEM of 
18 mice injected with CLL 
cells from three different 
cases (PA0146, GC0626, 
and GE1-BA101) are shown 
(Wilcoxon test). (C) Low- 
magnification image (top) 
of longitudinal sections of 
paraffin-embedded mouse 
spleen (CLL PA0146) double- 
stained for CD20 and Ki67. 
Spleen from mouse treated 
with isotype CTR (left) or 
IL-23p19 (right) mAb. Anal-
ysis at higher magnifica tion 
(×400) is shown (bottom). 
(D) IHC analysis of IL-23p19 
in spleens of mice treated 
as indicated in (A). (E and 
F) Dem onstration of apop-
totic neoplastic cells in both 
treated and control mice 
spleen by CD45/CD19/CD5/
annexin V staining and flow 
cytometry. (G) Dem onstra -
tion of Ki67-positive cycling 
cells by flow cytometry and 
(H) by confocal microscopy 
(magnification, ×200) in 
spleens of isotype CTR (top) or IL-23p19 mAb-treated mice (bottom). Microphotographs are representative of analyses on at least 10 for high-power magnification 
(×200, ×400) microscopic fields performed on each mouse tissue sample. The scatter dot plots in (B), (F), and (I) show data for each mouse, and mean values are calculated 
for each treatment mice group; statistical comparisons were carried out by Wilcoxon test. SSC-A, side scatter area.
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to activated CLL cells. The cells so opsonized could be subsequently 
killed by antibody-dependent cell- mediated cytotoxicity or comple-
ment activation. This conclusion stems from the observation of very 
few human CD16-positive cells in the proximity or within leukemic 
nodules in NSG mice (fig. S13A). Moreover, CLL cells activated 
in vitro by coculture with activated T cells and exposed to IL-23 
failed to bind IL-23p19 mAb (fig. S13B) and to fix complement 
(fig. S13C).
In an independent set of in vivo experiments, we investigated 
whether IL-23p19 mAb treatment could be effective in achieving a 
durable response in mice with rapidly progressive disease. Given that 
experiments in mice could not be prolonged for longer than 9 weeks 
because of possible excessive animal suffering, the experiments were 
designed as follows: 12 mice were injected with a higher number of 
PBMCs (100 × 106 cells per mouse) from CLL case SD36 (6 mice) or 
CLL case GE2-RL201 (6 mice) to obtain a more rapid engraftment 
with a high leukemic burden. Two weeks after cell injection, the aver-
age percentage of circulating leukemic cells (human CD45+CD19+CD5+ 
cells) in the 12 mice was 73.4 ± 2.6%. At this time point, therapy was 
administered with the same schedule described above (Fig. 7A): Six 
mice received IL-23p19 mAb (4 doses) and the other six received 
the isotype control mAb. Three weeks from the last mAb dose, mice 
were sacrificed, and IHC on spleen tissue sections was carried out 
(Fig. 8, A and B). CLL cells were also measured in the spleen, liver, 
bone marrow, and PBMCs by flow cytometry (Fig. 8C). The admin-
istration of a high number of leukemic cells caused the appearance 
of larger and more numerous infiltration foci in the mice spleen 
parenchyma, as observed by IHC for human CD20 staining. These 
foci were substantially reduced in number and size after IL-23p19 
mAb treatment. The actual relation of the infiltration foci with the 
CLL clones was documented by IGHV gene rearrangement analysis 
(Fig. 8, A and B, insets). The number of CLL cells infiltrating the 
different tissues was largely reduced in the IL-23p19 mAb–treated 
mice compared to controls at all sites tested by flow cytometry (P = 
0.03, Wilcoxon test) (Fig. 8C).
DISCUSSION
We have identified an autocrine/paracrine loop represented by the 
IL-23 complex expression and IL-23 production necessary for the 
clonal expansion of CLL cells (fig. S14). Inhibition of this loop with 
the appropriate mAb resulted in impaired viability and incapacity 
for CLL cell proliferation in vitro and prevented expansion of the leu-
kemic clones in NSG mice with a prolonged remission of the disease. 
Therefore, the IL-23R/IL-23 axis may represent a suitable target for 
CLL treatment.
The expression of the IL-23R complex and particularly of the 
“limiting” IL-12R1 chain was dependent on interactions with mi-
croenvironmental elements, as demonstrated by in vitro studies and 
corroborated by in situ observations on LN tissue sections showing 
the proximity between activated, IL-23R complex–expressing CLL 
cells with stromal macrophages and other CD40L+ cells. These 
data are also in line with observations in NSG mice, indicating that 
activated/proliferating Ki67+CD38+ CLL cells were also capable of 
expressing the IL-23R complex in vivo.
Expression of the IL-23R complex appears to be a multistep pro-
cess, characterized by the initial expression of the IL-23R and, sub-
sequently, by that of the IL-12R1. The progressive expression of 
these structures may be regulated by the cell activation status. CLL 
clones appear to be frozen at two particular stages: no receptor expres-
sion (IL-23Rlow CLL) or expression of the IL-23R only (IL-23Rhigh 
CLL). The IL-23Rlow and IL-23Rhigh phenotypes also distinguish two 
patient groups with different clinical features. Higher activation of 
IL-23Rhigh CLL clones may in part explain the more aggressive dis-
ease progression. Whether this stepwise process of IL-23R complex 
expression also characterizes the activation process of normal B cells 
and their response to IL-23 is presently unknown. However, the hy-
pothesis that CLL cells have a genetic defect, either germ line or 
somatic, which prevents a complete IL-23R complex expression 
(37), was ruled out by a number of observations, including the fact 
that IL-23R complex expression can be induced on CLL cells from 
both (IL-23Rhigh and IL-23Rlow) groups of patients in vitro and in NSG 
mice and that substantial expression of IL-23R complex was ob-
served in the NK cells and T cells of the same CLL patients.
The IL-23R complex/IL-23 loop was not induced by coculturing 
CLL cells with stromal cells or NLCs. Because both cell types do not ex-
press CD40L, these observations stress the requirement for a CD40L/
CD40 interaction in the activation of this autocrine/paracrine loop. 
Notably, the failure of NLCs and stromal cells to activate this loop 
was observed only when highly purified CLL cells (and not total PBMCs 
from the patients) were used in the coculture systems, indicating that 
the few activated T cells or other CD40L-expressing cells remaining 
in the PBMCs were sufficient to sustain IL-23 production and IL-23R 
complex expression. The involvement of the CD40/CD40L interac-
tions is also supported by the observation that BCR stimulation was 
unable to activate the IL-23R complex/IL-23 loop, even in the presence 
of IL-4 (33, 38), although BCR-derived signals may exert a regula-
tory role. For example, ibrutinib caused some inhibition of the IL-
23R complex induction in vitro in CLL cells activated via CD40L 
stimulation. Because there was a concomitant diminution of cell 
viability, this was likely related to the inhibition of the trophic effect 
normally exerted by BCR on B cells (39, 40). This inhibition of BCR- 
delivered trophic signals is likely to be responsible for most of the 
reduction of CLL cell clonal expansion caused by ibrutinib in NSG 
mice (41).
Signals of the IL-23R complex after binding to IL-23 are delivered 
via STAT3, as documented by the observation that exposure of acti-
vated CLL cells to IL-23 caused pSTAT3 increase as in previous studies 
(22, 42) and that this pathway was susceptible to the effect of JAK/
STAT inhibitors and was resistant to ibrutinib. Therefore, the JAK/
STAT pathway may represent an additional therapeutic target for 
CLL, independent of the BCR pathway.
IL-23 released by CLL cells may affect the patient T cell subset 
population composition and function, given its effects on T cells 
(fig. S14) (43). These considerations may help explain abnormal-
ities in T cell composition reported both in patients and in exper-
imental animals with CLL-like disease (44). IL-23 may facilitate 
the expansion of certain T cell subsets, instrumental in promoting 
CLL clonal expansion. The absence of this T cell support in NSG 
mice exposed to a neutralizing anti–IL-23 antibody would provide 
an explanation for the efficiency of the treatment in eradicating the 
engrafted leukemic clone. This hypothesis seems to be preferable to 
that of a direct cytotoxicity of IL-23p19 mAb on CLL cells growing 
in NSG mice.
Together, the above observations indicate that the activation of 
the IL-23R complex/IL-23 loop depends on a number of variables 
including CLL cell contact with CD40L-expressing cells, JAK/STAT 
pathway activation, and T cell composition. Moreover, these factors 
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require particular trafficking conditions in peripheral lymphoid tis-
sues, to efficiently exert their function, as documented by the hetero-
geneity of neoplastic cell distribution in the LNs and the relationship 
of these cells with different microenvironmental cell components. 
Given these considerations, it is not surprising to find different de-
grees of CLL activation among cell clones from different patients or 
to observe differences in the plasma levels of IL-23 as reported in 
another study (45). Unfortunately, such determination could not be 
performed in the present cohort because of the lack of sera availabil-
ity. Reevaluation of IL-23 mRNA levels in the circulating CLL cells 
from the patient cohort of this study, obtained from a previous gene 
expression profile investigation (28), revealed no correlation between 
the mRNA levels and the classification of a case as IL-23high or IL-23low, 
or the presence of unfavorable prognostic markers, possibly reiterat-
ing the concepts that the events occurring in peripheral lymphoid 
organs are the most relevant in determining the activation of the 
IL-23R complex/IL-23 loop, the levels of plasma IL-23, and perhaps the 
patient’s clinical course.
Inconsistent with the present observations are studies in different 
lymphoproliferative disorders that have reported either an inhibito-
ry effect of IL-23 on the growth of the neoplastic cells (DLBCL, FL, 
and ALL) or no effect (myeloma) (23–26). The reasons for these discrep-
ancies are presently obscure. Tentatively, one could speculate that cells 
from different neoplasms could respond differently to IL-23 expo-
sure, owing to differences in activation status in vivo.
The in vivo xenograft experiments demonstrated the effective de-
pendence of IL-23R complex regulation by the tissue microenviron-
ment. Notably, we did not find any differences in CLL cell engraftment 
in NSG mice of clones classified as either IL-23high or IL-23low. This 
observation may have two non–mutually exclusive explanations: (i) that 
engraftment was greatly facilitated not only by the presence of the 
patient T cells but also by their preactivation step with CD3/CD28 
beads and IL-2 to which all CLL PBMC suspensions are routinely 
subjected before inoculation in our laboratory, or (ii) that the mu-
rine environment represented a suitable milieu for the full activation 
of the IL-23R complex/IL-23 loop. The present experiments demon-
strated the efficacy of a mAb-based interference of the IL-23R/IL-23 
axis in CLL disease control and eradication. The use of an IL-23p19 
antibody, currently adopted in the clinical setting for the treatment 
of autoimmune diseases (46), represents a strong prospect for the 
translation of the results from our in vivo animal studies, although 
they were limited to a single model dependent on immunodeficient 
mice. This study indicates that the JAK/STAT pathway may repre-
sent an additional suitable therapeutic target for CLL, as in diseases 
characterized by IL-23–driven lymphocyte proliferation. Thus, an anti– 
IL-23 mAb and JAK/STAT inhibitor alone or in combination may 
represent a future tool for the treatment of a disease that, so far, ap-
pears to be incurable (47, 48).
MATERIALS AND METHODS
Study design
The aim of this work was to determine the role of the IL-23R/IL-23 
autocrine loop in CLL clonal survival/expansion and to ascertain 
Fig. 8. IL-23p19 induces regression of the leukemic clone for a prolonged pe-
riod. Mice were injected with 100 × 106 CLL cells per mouse (CLL GE2-RL201). After 
2 weeks, blood samples were evaluated for the presence of circulating leukemic 
cells before treatment with four doses of IL-23p19 or isotype CTR mAb every 2 days. 
Three weeks after the last mAb dose, mice were sacrificed, and the spleen, liver, BM, 
and peripheral blood were analyzed by IHC and flow cytometry. (A and B) Low- 
magnification image of longitudinal sections of paraffin-embedded mouse spleen 
stained with CD20-Ab. The insets show infiltrating foci observed at higher magni-
fication (×200). Black peaks indicated by the arrows in the graph insets show the 
presence of B cell receptor gene rearrangement of the leukemic clone as assessed 
by fragment length analysis. Microphotographs are representative of analyses 
on at least 10 microscopic fields performed on each mouse spleen tissue sample. 
(C) Spleen, liver, BM, and peripheral blood samples analyzed by flow cytometry for 
percentage of neoplastic B cells (CD5+CD19+ cells). The mean and SEM of 12 mice 
injected with CLL cells from two different cases (SD36 and GE2-RL201) are shown 
(Wilcoxon test).
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whether this loop is drug-targetable. This study was generated by the 
observation that cells from CLL clones can express different levels 
of IL-23R and that CLL cases classified as IL-23Rhigh have a shorter 
TTFT than cases classified as IL-23low. Therefore, IL-23R could con-
ceivably be part of a series of events leading to clonal expansion. To 
investigate this hypothesis, we first studied whether a fully functional 
IL-23R complex could be induced on CLL by a number of stimuli. 
CLL cells from both IL-23high and IL-23low patient groups expressed 
IL-23R complex and began to secrete IL-23 when activated in vitro 
by contact with CD40L-expressing cells. This activation process was 
accompanied by increased cell viability, by decreased spontaneous 
apoptosis, and by cell proliferation. To investigate whether this CD40L- 
mediated activation process also occurred in vivo, we first observed LN 
from CLL patients by IHC and found that IL-23R complex–expressing 
and IL-23–secreting CLL cells were located primarily at sites enriched 
of CD40L+ cells. To further investigate the potential role of an IL-23R 
complex/IL-23 autocrine/paracrine loop, we inoculated the CLL cells 
into NSG mice together with activated autologous T cells. Groups of 
these mice were treated with a neutralizing IL-23p19 mAb, whereas 
control mice received an irrelevant mAb. IL-23p19 mAb–treated 
mice displayed a substantial inhibition of CLL cell growth compared 
to control mice. In situ studies showing IL-23 production as well as 
IL-23R complex expression particularly at the site of CLL cell growth 
expansion confirmed this notion.
Data are presented as mean ± SEM or mean ± SD, which were cal-
culated invariably from n (the number of patients or animals, bio-
logical replicates). Primary data are reported in table S5.
Statistical analysis
The statistical software package SPSS for Windows, v.13.0, 2004 
(SPSS UK), was used for all analyses. For categorical variables, statis-
tical comparisons were performed using two-way tables for Fisher’s 
exact test and multiway tables for Pearson’s chi-square test. Statistical 
comparisons between related samples were carried out by Wilcoxon 
or Mann-Whitney U tests.
The best cutoff point for IL-23R expression able to discriminate 
cases that progressed from those that did not progress was sought 
by constructing ROCs. TTFT analyses were performed using the 
Kaplan- Meier method. Statistical significance of associations between 
individual variables and survival was calculated using the log-rank 
test. The prognostic impact for the outcome variable was investigat-
ed by univariate and multiple Cox regression analysis. Data are ex-
pressed as HR and 95% CI. To assess the internal validity of univariate 
and multivariate Cox regression models, we performed a bootstrap 
resampling technique of 1000 samples (49). P < 0.05 was considered 
significant for all statistical calculations. Values are given as mean ± 
SEM or mean ± SD.
SUPPLEMENTARY MATERIALS
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xenograft mouse model. These promising results could open up new avenues of treatment for CLL.
IL-23 antibody could slow tumor growth in a−cytokine in a survival feedback loop and demonstrated that an anti
 LL cells could also produce IL-23 in vitro. The authors reasoned that the cells could produce and respond to this
receptor on biopsies from early-stage CLL patients, and higher expression was associated with poor prognosis. C
. observed differential expression of the IL-23et alexpansion and survival are not completely understood. Cutrona 
Chronic lymphocytic leukemia (CLL) cells are derived from B cells, but the exact signals that drive their
Interrupting IL-23 signaling could curb CLL
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